Literature DB >> 25917365

Variables determining the development of colistin-associated renal impairment.

Bahadır Ceylan1,2, Müdür Taniş3, Muhammed Emin Akkoyunlu4, Ahmet Çınar5, Ayşe Ruhkar Kurt6, Yasemin Akkoyunlu6, Didem Ozkan4, Hatice Kutbay Ozcelik4, Turan Aslan6, Muzaffer Fincancı3, Şule Vatansever7, Kadir İdin8, Emine Guler8, Harun Uysal8.   

Abstract

AIM: The aim of this study was to identify the predictors of acute renal injury associated with colistin treatment.
METHODS: The patients who received treatment with colistin for more than 3 days were included in this retrospective cohort study. Acute renal injury was defined by the RIFLE (Risk Injury Failure Loss End stage renal disease) criteria. Patients whose serum creatinine levels increased at least 1.5-fold compared with baseline value were considered as cases with renal injury. The independent variables determining the development of acute renal injury were investigated by survival analysis.
RESULTS: A total of 112 cases [67 (59.8 %) were male, median age 64 (range: 18-93) years] were included in the study. Acute renal injury occurred in 66 (58.9 %) patients. Renal injury developed in first 7 days of the colistin therapy in 52 (78.8 %) cases and at day 8-23 in 14 (21.2 %) cases. On the day with highest levels of creatinine, 25 (22.3 %), 17 (15.2 %), and 33 (29.5 %) cases were in 'Risk', 'Injury', and 'Failure' group, respectively, according to RIFLE criteria. We identified three independent risk factors predicting acute colistin-induced renal injury: advanced age, low serum albumin levels, and high serum total bilirubin levels [odds ratio (confidence interval) = 1.022 (1.006-1.037), 0.643 (0.415-0.994), and 1.129 (1.014-1.257), respectively].
CONCLUSIONS: The advanced age, low serum albumin levels, and high serum total bilirubin levels are independent risk factors for colistin-induced nephrotoxicity.

Entities:  

Keywords:  Acute renal injury; Adverse effects; Colistin; Drug-induced abnormalities; Renal tubulopathy

Mesh:

Substances:

Year:  2015        PMID: 25917365     DOI: 10.1007/s00508-015-0773-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  39 in total

1.  Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin.

Authors:  Hee ja Ko; Min hyok Jeon; Eun ju Choo; Eun jung Lee; Tae hyong Kim; Jae-Bum Jun; Hyo-Wook Gil
Journal:  Nephron Clin Pract       Date:  2010-09-17

2.  Colistin dosing and nephrotoxicity in a large community teaching hospital.

Authors:  C Andrew Deryke; Amanda J Crawford; Nizam Uddin; Mark R Wallace
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

3.  Effectiveness and safety of colistin: prospective comparative cohort study.

Authors:  Mical Paul; Jihad Bishara; Ariela Levcovich; Michal Chowers; Elad Goldberg; Pierre Singer; Shaul Lev; Perla Leon; Maria Raskin; Dafna Yahav; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2010-03-18       Impact factor: 5.790

Review 4.  Definition and classification of acute kidney injury.

Authors:  John A Kellum; Rinaldo Bellomo; Claudio Ronco
Journal:  Nephron Clin Pract       Date:  2008-09-18

5.  Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients.

Authors:  Timothy P Gauthier; William R Wolowich; Arathi Reddy; Ennie Cano; Lilian Abbo; Laura B Smith
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

6.  Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics.

Authors:  Jumana M Yousef; Gong Chen; Prue A Hill; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2011-11-28       Impact factor: 5.790

7.  Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections.

Authors:  M Bassetti; E Repetto; E Righi; S Boni; M Diverio; M P Molinari; M Mussap; S Artioli; F Ansaldi; P Durando; G Orengo; F Bobbio Pallavicini; C Viscoli
Journal:  J Antimicrob Chemother       Date:  2008-01-03       Impact factor: 5.790

8.  Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections.

Authors:  Chien-Yu Cheng; Wang-Huei Sheng; Jann-Tay Wang; Yee-Chun Chen; Shan-Chwen Chang
Journal:  Int J Antimicrob Agents       Date:  2009-12-31       Impact factor: 5.283

9.  The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections.

Authors:  Seung-Kwan Lim; Sang-Oh Lee; Seong-Ho Choi; Jae-Phil Choi; Sung-Han Kim; Jin-Yong Jeong; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim
Journal:  J Korean Med Sci       Date:  2011-02-25       Impact factor: 2.153

10.  Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections.

Authors:  Ronald Gounden; Colleen Bamford; Richard van Zyl-Smit; Karen Cohen; Gary Maartens
Journal:  BMC Infect Dis       Date:  2009-03-09       Impact factor: 3.090

View more
  2 in total

1.  Colistin induced acute kidney injury in critically ill children: a prospective study utilizing RIFLE criteria.

Authors:  Sharifzadeh Meysam; Zahra Khosravi; Roshanak Rashti; Mostafa Qorbani; Farahnak Assadi; Alireza Hayatshahi; Tanzifi Parin; Toktam Faghihi
Journal:  Daru       Date:  2021-11-22       Impact factor: 4.088

Review 2.  Causal relationship between hypoalbuminemia and acute kidney injury.

Authors:  Christian J Wiedermann; Wolfgang Wiedermann; Michael Joannidis
Journal:  World J Nephrol       Date:  2017-07-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.